This is a working overview of bremelanotide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
| Property | Value | Notes |
|---|---|---|
| Primary receptor target | MC4R agonist | Subtype most often linked to behavioural effects |
| Other reported targets | MC1R, MC3R, MC5R | Activity is not selective for a single subtype |
| Endogenous ligand class | Melanocortin peptides | Alpha-MSH and ACTH act on the same family |
| Peptide architecture | Cyclic heptapeptide | Lactam bridge between the aspartate and lysine residues |
| Central action | Inferred from animal models | Not directly measured in the human brain |
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
==== Comparison of pharmacokinetics between dosage forms ==== The free acid (HMB-FA) and monohydrated calcium salt (HMB-Ca) forms of HMB have different pharmacokinetics. HMB-FA is more readily absorbed into the bloodstream and has a longer elimination half-life (3 hours) relative to HMB-Ca (2.5 hours). Tissue uptake and utilization of HMB-FA is 25–40% higher than for HMB-Ca. The fraction of an ingested dose that is excreted in urine does not differ between the two forms.
Lansoprazole was the second of the PPI drugs to reach the market, being launched in Europe in 1991 and the US in 1995. It has no substitutions at the benzimidazole but two substituents on the pyridine, methyl group at position 3 and a trifluoroethoxy group at position 4. The drug is a 1:1 racemate of the enantiomers dexlansoprazole and levolansoprazole. It is available in gastroresistant capsules and tablets as well as chewable tablets.
Pharmacy Practice (pharmacist) Pharmaceutics (drug development, drug discovery) and Computational Pharmaceutics Medicinal Chemistry (drug design) and Pharmacognosy Pharmacology (includes pharmacokinetics and pharmacodynamics) Pharmacoinformatics Pharmacogenomics The boundaries between these disciplines and with other sciences, such as biochemistry, are not always clear-cut. Often, collaborative teams from various disciplines (pharmacists and other scientists) work together toward the introduction of new therapeutics and methods for patient care. However, pharmacy is not a basic or biomedical science in its typical form. Medicinal chemistry is also a distinct branch of synthetic chemistry combining pharmacology, organic chemistry, and chemical biology. Pharmacology is sometimes considered the fourth discipline of pharmacy. Although knowledge of pharmacology is essential to the study of pharmacy, both disciplines are distinct. Those who wish to practice both pharmacy (patient-oriented) and pharmacology (a biomedical science requiring the scientific method) receive separate training and degrees unique to either discipline. Pharmacoinformatics is considered another new discipline, for systematic drug discovery and development with efficiency and safety. Pharmacogenomics is the study of genetic-linked variants that effect patient clinical responses, allergies, and metabolism of drugs.
==== Nucleic acid-based molecules ==== Nanogels are advantageous carriers of small, nucleic-acid based molecules that can be employed to treat a variety of diseases. Examples of three different types of molecules that fall into this category, oligonucleotides, miRNA, and nucleoside analogs, are discussed here. In one study, cationic synthetic nanogels modified with insulin and transferrin were synthesized to transport oligonucleotides, a possible therapeutic and diagnostic tool for neurodegenerative disorders, to the brain. These nanogels successfully localized through an in vitro model of the blood-brain barrier and accumulated in the brain in a mouse model. With the treatment of cardiovascular diseases in mind, polysaccharide-based nanogels have been functionalized with fucoidan to target overexpressed P-selectin receptors on platelets and endothelial cells. After loading with miRNA, these nanogels bound to platelets and became internalized by an endothelial cell line. Nanogels have also been used to encapsulate phosphorylated nucleoside analogs, or active forms of anticancer therapeutics. In one study, nanogels loaded with nucleoside 5'-triphosphates underwent surface modifications and successfully bound to overexpressed folate receptors on breast cancer cells. These nanogels were then internalized by the cells and produced a significant increase in cytotoxicity compared to control groups.
Such covers, including both "Part of Your World," and "Think of Me" from Phantom of the Opera, have become available to purchase on sites such as Spotify. As an author, in 2015, Pansino wrote and published The Nerdy Nummies Cookbook. The book included selected recipes previously featured on Nerdy Nummies, along with previously featured recipes which were remastered. The book became a New York Times best seller and was listed by Book Riot as one of "50 Must-Read Books by YouTubers". In 2018, Pansino released another cookbook entitled, Baking All Year Round, which was based on the same concept of her previous cookbook. Pansino began her business ventures in August 2017, releasing a baking line in collaboration with the bakeware company Wilton. The line consisted of cooking tools and products primarily intended for use by beginners, with items including color coding and line gauges. It was released to a number of retailers, including Walmart and Michael's. In 2018, she released new items to further extend her line. In 2022, she also collaborated with iDesign to create a kitchen and home organization line distributed by The Container Store, consisting of various items including mixing bowls, turntables, and storage containers. She began hosting in 2019, making an appearance as a guest judge on the Netflix original competitive baking show Nailed It!. In 2020, she appeared on YouTuber Lauren Riihimaki's show Craftopia.
Sources: en.wikipedia.org
== Education == Greenspan studied at New York University College of Arts & Science and graduated in 1974. His graduate studies were on the SV40 large T-Ag oncogene of the SV40 DNA virus. He received his master's degree in 1978, and Doctoral degree in 1981 from New York University Medical School.
As of 2017, the Panda Restaurant Group had annual sales of over $3 billion and close to 39,000 employees. The Cherngs also opened Panda Innovation Kitchen in Pasadena with their daughter, Andrea Cherng, overlooking a majority of the restaurant's business. The idea for Panda Innovation Kitchen is to experiment with new flavours and ingredients to come up with new menu items. In addition, they also opened a tea bar to introduce Taiwanese drinks such as boba milk tea and new drinks like the Fortune Cookie Shake.In December 2017, Panda Express had opened the chain's 2,000th location, which is located in New York City near Columbia University. In February 2022, Panda Restaurant Group filed a U.S. trademark application for the name PANDAVERSE for "downloadable virtual goods, namely, food items and beverages for use in virtual worlds" and "virtual food and beverage products." The filing marked an intention to expand the Panda Express brand into the Metaverse. In March 2022, Panda Express committed to transitioning to 100% cage-free eggs, responding to pressure from animal welfare groups.
Array analysis has become a standard technique for molecular biologists who wish to monitor gene expression. DNA ink-jet printer technology has had a significant impact on genomics, biology, and medicine.
Parathyroid hormone-related protein (PTHrP) is a proteinaceous hormone and a member of the parathyroid hormone family secreted by mesenchymal stem cells. It is occasionally secreted by cancer cells (for example, breast cancer, certain types of lung cancer including squamous-cell lung carcinoma). However, it also has normal functions in bone, teeth, vascular tissues and other tissues.
Sources: en.wikipedia.org
Peritenon (from peri-: around, tenon: tendon) is the connective tissue sheath surrounding a tendon. Inflammation of a peritenon is called "peritendinitis" or "peritenonitis". Although Achilles tendon has no synovial sheath, it has a peritenon instead which has the same function.
== Stem cell treatments == Haematopoietic stem cells (HSC) are cells in the bone marrow that can develop into all types of blood cells, including red blood cells, white blood cells, and platelets. There are two possible ways to treat sickle cell disease and some other hemoglobinopathies by targeting HSCs. Since 1991, a small number of patients have received bone marrow transplants from healthy matched donors. This procedure is high-risk. More recently, it has become possible to use CRISPR gene editing technology to modify the patient's own HSCs in a way that reduces or eliminates the production of sickle haemoglobin HbS and replaces it with a non-sickling form of haemoglobin. All stem cell treatments must involve myeloablation of the patients' bone marrow to remove HSCs containing the faulty gene. This requires high doses of chemotherapy agents with side effects such as sickness and fatigue. A long hospital stay is necessary after infusion of the replacement HSCs, while the cells take up residence in the bone marrow and make red blood cells with the stable form of haemoglobin.
William Henry Vanderbilt* (1841), eldest son of Cornelius Vanderbilt; president of the New York Central Railroad, Lake Shore and Michigan Southern Railway, Canada Southern Railway, and Michigan Central Railroad Robert Morrison Olyphant (1842), heir to trading company Olyphant & Co. and president of the Delaware and Hudson Railway Charles Carow* (1844), businessman son of shipping magnate Isaac Carow, father of first lady Edith Carow Roosevelt Frederic W. Rhinelander (1847), 3rd president of the Metropolitan Museum of Art William Backhouse Astor Jr. (1849), son of William Backhouse Astor Sr. and husband of Caroline Webster Schermerhorn Astor, co-founder of The Four Hundred list of socialites and Florida Yacht Club Robert L. Cutting Jr. (1856), banker and clubman, son of Robert L. Cutting '30 George Lovett Kingsland (1856), merchant and railroad executive, son of New York City mayor Ambrose Kingsland Goold H. Redmond (1857), banker and sportsman Charles Henry Marshall (1858), businessman, former commissioner of Docks and Ferries of the City of New York, grandfather of publisher Marshall Field IV John Crosby Brown (1859), heir to investment bank Brown Bros. & Co., which later became Brown Brothers Harriman & Co., the oldest private bank in the U.S. Emory McClintock (1859), actuary; president of the American Mathematical Society and the Actuarial Society of America Robert Goelet (1860), real estate developer Rutherfurd Stuyvesant (1863), socialite, heir to the Stuyvesant family fortune J.
Sources: en.wikipedia.org
Bremelanotide binds several melanocortin receptors, and MC4R is the subtype most often cited as responsible for its behavioural effects. Activity at MC1R, MC3R and MC5R is also reported. Selectivity is therefore described as limited rather than precise.
It is not classified as a vasodilator, and its proposed site of action is the central nervous system rather than peripheral vessels. Some trial participants show small transient blood pressure changes. Whether those changes arise centrally or through another route remains an open question.
Most evidence comes from animal models and from indirect human outcomes such as self-reported desire. Direct measurements of receptor occupancy or signalling in the human brain are not available. Published reviews therefore present a plausible pathway rather than a confirmed sequence of events.
It is frequently described as an MC4 receptor agonist, but binding assays show activity at more than one melanocortin subtype. Selectivity is therefore relative rather than absolute. This matters when interpreting side effects tied to other receptor subtypes.